Alumis 3Q 2026: Revenue $1.91M, EPS ($0.73) — 10-Q Summary
Alumis reported 3Q 2026 revenue of $1.91M, down 8% YoY, with a net loss of $94.88M, improved 14% YoY. R&D expenses fell 17% due to completed trials. The company plans an NDA submission for envu in psoriasis by year-end and is exploring strategic alternatives for lonigutamab.
How this was made
The 30-second read
Why it matters
The disclosed Phase 2b envu results provide a new data point for the company's psoriasis NDA plan, potentially influencing valuation.
Market read
First public disclosure of trial data and financials; relevant for biotech traders.
What to watch
Reduced R&D spend may signal limited pipeline depth beyond envu.
Background
Alumis filed its Form 10‑Q for Q3 2026, showing modest revenue decline and a narrowed net loss.
Ticker impact
Alumis reported Q3 2026 results with revenue $1.91M and disclosed topline Phase 2b envu trial data in systemic lupus erythematosus.
likely upward pressure as market prices in favorable trial results
Trial data is a material catalyst for a biotech; investors typically bid up stocks on positive early‑stage results.
Market effects
May boost sentiment for biotech firms with late‑stage trial pipelines.
Limited to US biotech investors.
Minimal global impact beyond sector.
Counterpoint
Trial data could be preliminary; investors may wait for Phase 3 results before committing.
Key entities
- companyAlumis Inc.
Biotech company developing envu for psoriasis and lupus.
